Goldman Sachs has initiated coverage of GRAIL, Inc. (NASDAQ:GRAL) with a Neutral rating and a price target of $60.00, noting the stock's current trading price of $66.55 may indicate overvaluation. Analyst Evie Koslosky highlighted uncertainties surrounding FDA approval and reimbursement as significant factors influencing GRAIL's growth potential. The company is not expected to achieve profitability this year, with a projected loss of $10.31 per share. GRAIL's Galleri test, which detects multiple types of cancer from a single blood draw, has begun to penetrate the self-pay market. Despite these challenges, GRAIL reported first-quarter 2026 revenues of $40.8 million, exceeding analyst expectations. Additionally, Wolfe Research has initiated coverage with a Peerperform rating, suggesting a fair value range of $55 to $80 for GRAIL shares. The ongoing PATHFINDER 2 study results indicate a significant increase in cancer detection rates when the Galleri test is used alongside standard screenings.